News and commentary from the endocrinology world
— News and commentary from the endocrinology world
May 19, 2026
• 2 min read
GLP-1 medication use increased by 140.4% from 2022 to 2024 while metabolic bariatric surgery utilization declined by 34.1%, national insurance data indicated. (JAMA Surgery)
Generic forms of semaglutide (Ozempic, Wegovy) aren't expected in the U.S. until at least 2031, despite being available in other countries. (NBC News)
Obesity is a chronic disease. This statement is clearly at the heart of the answer to this question. When you look at the data in…
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy.The…
Weight loss likely not the only reason for improvement, researcher says
Companies have “tremendous concern” about the financial viability of these medications, the president and CEO of the Business…
GLP-1 receptor agonists may help improve outcomes among women with breast cancer and chronic cardiometabolic diseases, results of…
